(Human Papillomavirus) is one of the leading causes of cervical cancer, and early detection can significantly reduce the risk of developing the disease!
What is HPV?
HPV is one of the most common sexually transmitted viruses globally. HPV infection is associated with various diseases, including genital warts, cervical cancer, and oropharyngeal cancer. Previous studies have shown that most
sexually active men and women will contract genital HPV at least once in their lifetime.
Why is HPV testing so important?
HPV infections often show no obvious symptoms, but long-term infection can lead to serious diseases like cervical cancer. Regular HPV testing can detect the virus early, allowing for timely intervention to protect your health
How scary are the “hidden dangers” of HPV? The crisis is closer than you think!
The HPV virus is like a silent “health assassin”:
1. 80% of women may contract HPV in their lifetime, but 90% of those infected show no symptoms!
2. Persistent infection with high-risk HPV → cervical cancer (over 340,000 women die from it globally each year❗)
3. The cancer risk isn’t just for women! The infection rate in men is equally alarming: U.S. studies show that 45% of men carry the HPV virus in their genital area.HPV can also lead to anal cancer, oropharyngealcancer,penile cancer, and more.
4. The terrifying truth: It’s hard to detect in the early stages of infection! It can take up to 10 years from infection to cancer development, but early detection can completely block it.
The silent progression of the disease:
Infection → Persistent infection → Precancerous lesions → Cancer, the entire process may occur without any warning!
▸ CIN1 lesions: Reversible stage, cure rate > 90%
▸ CIN3 lesions: Just one step away from cancer
▸ Once it progresses to invasive cancer, surgery may require the removal of the uterus, and can even be life-threatening.
WHO’s Response:
All countries have made a commitment to eliminate cervical cancer as a public health problem. The WHO Global strategy defines elimination as reducing the number of new cases annually to 4 or fewer per 100 000 women and
sets three targets to be achieved by the year 2030 to put all countries on the pathway to elimination in the coming decades:
90% of girls vaccinated against HPV by the age of 15
70% of women screened with a high-performance test by the ages of 35 and 45
90% of women with cervical disease receiving treatment.
Why is regular HPV testing essential?
Earlier than symptoms: Cervical lesions are painless and symptom-free in the early stages; by the time bleeding or pain occurs, it may already be in the middle or late stages.
Protect your partner: HPV is transmitted through sexual contact; one person’s infection can threaten the health of both parties.
Precise defense: If the test is negative → peace of mind + regular screening; if positive → early intervention (vaccine + treatment).
Save lives: The cure rate for early-stage cervical cancer is over 90%, while the survival rate for late-stage is less than 20%.
Why is a “double insurance” defense necessary? Debunking myths!
Having received the HPV vaccine ≠ 100% protection! Regular testing is still required.
Men can also carry and transmit high-risk HPV!
The vaccine only protects against 70%-90% of high-risk types and is ineffective against already infected types!
“Normal physical exam = no HPV?” Routine gynecological exams cannot detect the virus, and the TCT false-negative rate is as high as 50%!
Scientific Protection Formula:
Annual Rapid Test + HPV Vaccine + Regular TCT = Golden Cancer Prevention Combo
Especially when testing positive:
▸ Positive → Immediate colposcopy biopsy + enhanced monitoring + immune regulation
▸ Couples simultaneous testing → Cut off the transmission chain
Women
- Women aged 25 and above with sexual experience: The peak period for HPV infection is between 25-35 years old. Screening is recommended starting at age 25.
- Women who have received the HPV vaccine: The vaccine does not cover all high-risk types, so regular testing is still necessary.
- Women with a history of cervical lesions: Even if cured, the risk of recurrence is higher, requiring enhanced monitoring.
- Women planning pregnancy: Pre-pregnancy testing can avoid HPV-related complications during pregnancy.
Men
- Men with sexual experience: Men are important carriers of HPV transmission. Testing can protect themselves and their partners.
- Men with genital warts or abnormal symptoms: These may be signs of HPV infection and require prompt testing.
- Men who have sex with men (MSM): Higher risk of anal HPV infection, so regular screening is recommended.
Other High-Risk Groups
- Immunocompromised individuals: Such as HIV patients or organ transplant recipients, who are more likely to develop cancer after HPV infection.
- Individuals with multiple sexual partners or high sexual activity: The risk of infection increases with the number of sexual partners.
- Individuals with a family history of HPV infection: Genetic susceptibility may exist, requiring earlier screening.
General Population (Aged 25-65)
1. Initial HPV screening negative: Test every 3-5 years (combined with TcT results).
2. HPV positive but no lesions: Test annually until the result turns negative.
3. HPV positive with abnormal TcT: Follow doctor’s advice, retest every 6-12 months.
High-Risk Groups
1.lmmunocompromised individuals: Test every 6-12 months.
2. Individuals with a history of cervical lesions: After treatment, test every 6 months; if resultsare negative for 2 consecutive years, extend to annual testing.3. High-risk men: Test annually, especially those with symptoms or high sexual activity.
Individuals Aged 65 and Above
1. Normal previous screening results: Screening may be stopped (requires doctor’s evaluation).
2. History of lesions or high-risk factors: Continue regular testing.
Jinwofu HPV Rapid Test – Press the “Pause Button” for Health
No need for awkward doctor visits, home sampling completed in 5 minutes.
Advantages of Jinwofu Rapid Test:
Scientific Basis for HPV Testing
1. Reducing cervical cancer risk: HpV testing significantly reduces incidence and mortality rates(Ronco et al., 2014; Arbyn et al.. 2020).
2. lmproving early lesion detection rate: Sensitivity is significantly higher than cytology testing(Schiffman et al., 2011:Wentzensen et al., 2021).
3. Protecting men’s health: HPV infection in men is associated with various cancers (Giuliano etal.. 2011: Han et al., 2022).
4. Testing still required after vaccination: Vaccines do not cover all high-risk types (Drolet et al.
2019; Garland et al.. 2018).
Email：xinxi@jwfbio.com Website：www.jwfbio.com whatsapp:+86-15733226318
Post time: Feb-18-2025